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Abstract
Endoglin, a type I membrane glycoprotein expressed as a disulfide-linked homodimer on human vascular endothelial cells,
is a component of the transforming growth factor (TGF)-b receptor complex and is implicated in a dominant vascular
dysplasia known as hereditary hemorrhagic telangiectasia as well as in preeclampsia. It interacts with the type I TGF-b
signaling receptor activin receptor-like kinase (ALK)1 and modulates cellular responses to Bone Morphogenetic Protein
(BMP)-9 and BMP-10. Structurally, besides carrying a zona pellucida (ZP) domain, endoglin contains at its N-terminal
extracellular region a domain of unknown function and without homology to any other known protein, therefore called the
orphan domain (OD). In this study, we have determined the recognition and binding ability of full length ALK1, endoglin
and constructs encompassing the OD to BMP-9 using combined methods, consisting of surface plasmon resonance and
cellular assays. ALK1 and endoglin ectodomains bind, independently of their glycosylation state and without cooperativity,
to different sites of BMP-9. The OD comprising residues 22 to 337 was identified among the present constructs as the
minimal active endoglin domain needed for partner recognition. These studies also pinpointed to Cys350 as being
responsible for the dimerization of endoglin. In contrast to the complete endoglin ectodomain, the OD is a monomer and its
small angle X-ray scattering characterization revealed a compact conformation in solution into which a de novo model was
fitted.
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Introduction
Endoglin, a TGF-b co-receptor expressed in endothelial cells,
plays a key role in cardiovascular development, angiogenesis and
vascular remodeling and homeostasis [1,2,3]. Mutations in the
human ENDOGLIN gene (ENG) are responsible for Hereditary
Hemorrhagic Telangiectasia (HHT) type 1, a disease character-
ized by frequent nose bleeds, telangiectases on skin and mucosa
and arteriovenous malformations in lung, liver and brain [4,5,6].
Interestingly, ectodomain shedding of the membrane-bound
receptor may occur under certain physiological conditions, and
the plasma levels of this soluble endoglin form are highly increased
and play a major pathogenic role in preeclampsia, a systemic
syndrome of pregnancy which is associated with significant
morbidity and mortality of both mothers and fetuses and which
is characterized by pregnancy-associated hypertension and
proteinuria [3]. Endoglin expression is markedly upregulated in
proliferating endothelial cells, playing a crucial role in angiogenesis
during development and in adult animals [1,3,7]. Indeed, endoglin
knockout mice die in utero due to defects in the vascular system
[8,9,10]. Cellular morphology, migration and adhesion [11] as
well as cell responses to different members of the TGF-b family,
including BMP-9 [12,13] are modulated by endoglin. It has been
postulated that endoglin’s capacity to modulate TGF-b signaling is
due to its ability to interact with the signaling type I receptors
ALK5 and ALK1 and with the type II TGF- b receptor [5,14,15].
Several lines of experimental evidence support the notion that
endoglin potentiates ALK1 signaling, including the fact that
mutations in the gene coding for ALK1 (ACVRL1) give rise to a
second form of HHT (HHT2) [5,6]. Signaling triggered by the
BMP-9-dependent ALK1/endoglin route mediates through the
Smad1/5/8 pathway the expression of a vast number of genes,
including the gene for the inhibitor of differentiation 1 (ID1), a
negative transcriptional regulator which is associated with the
development of malignant melanoma [2,5,14]. In addition, a
crosstalk between the BMP-9/ALK1/endoglin route and that of
TGF-b1/ALK5/Smad2,3 has also been reported in endothelial
cells [2,14,16]. In this regard, ALK1 and endoglin are able to
inhibit the TGF-b1/Smad3-mediated responses [1,13,15,16,17].
However, at variance with TGF-b1, BMP-9 has shown high
specificity in ligand binding and signaling for endoglin and ALK1
receptors [18,19,20,21]. Because of this specificity, BMP-9 has
been postulated as the physiological ligand of the ALK1/endoglin
pathway in HHT [12,22].
Human endoglin is a 180 kDa homodimeric transmembrane
protein that contains a 561- residue extracellular domain and a 47-
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ly, endoglin belongs to the zona pellucida (ZP) family of
extracellular proteins that share a ZP domain consisting of about
260 amino acids with eight conserved cysteine residues close to the
transmembrane region [24,25,26]. This consensus ZP domain is
located in the Lys362-Asp561 region of the endoglin ectodomain.
Endoglin is highly glycosylated, in agreement with the reported
potential O-linked glycosylation sites at Asn88, Asn102, Asn121,
Asn134 and Asn307 [23]. The three-dimensional structure of the
extracellular domain of endoglin at 25 A ˚ resolution, determined
by single-particle electron microscopy, showed that endoglin is
arranged as a dome made of antiparallelly- oriented monomers
enclosing a cavity at one end [25]. Each subunit comprises three
well-defined regions, two of them corresponding to the ZP
domains. The third region does not show any significant homology
to other protein consensus motif/domain and thereby has been
named the ‘‘orphan’’ domain (OD) [25]. Moreover, Small Angle
X-ray Scattering (SAXS) experiments revealed an elongated
conformation for soluble endoglin in solution, suggesting that
endoglin might undergo conformational adaptations upon ligand
binding [27]. A high resolution 3D structure remains to be
determined. In this study, we have expressed recombinant versions
of the extracellular full length domain of endoglin and of the OD.
The ability of these constructs to recognize and bind BMP-9, both
on their own account and in concert with ALK1, was examined by
Surface Plasmon Resonance (SPR). Also, the recombinant OD of
endoglin was structurally analyzed by SAXS experiments,
revealing a compact conformation in solution into which a de
novo model was fitted. While this manuscript was in preparation, a
similar study by Castonguay and colleagues was published [28].
Therein the authors used immunoglobulin Fc domain tagged
constructs, leading to slightly different results from ours, but
reaching the same general conclusion, namely that the OD is
responsible for ligand recognition and that binding of endoglin
and ALK1 to their common ligand is unlikely to be cooperative.
Results
Soluble TGF-beta receptors are successfully expressed in
HEK293 cells
Previous results from our and other laboratories show that
endoglin and ALK1 are not expressed well in Escherichia coli or in
Saccharomyces cerevisiae [29,30] where the produced protein is either
not soluble or it aggregates and can only be purified in oligomeric
forms which are unsuitable for structural and functional
characterizations [31]. We therefore opted for expressing the
ectodomains of these proteins in human cells, which should
approach more the normal environment of these proteins and are
capable of dealing with the necessary post-translational modifica-
tions to render correctly folded soluble proteins. Constructs for
expressing the full length extracellular region of human endoglin
(EndoEC, residues 22–587) and the truncated constructs Endo338
(residues 22–337) and Endo362 (residues 22–362) (Figure 1A) were
cloned into the pOPING vector [32], which allows for secretion of
the protein into the medium. The constructs were successfully
overexpressed as soluble proteins in glycosylation-impaired
HEK293S GnTI- suspension-grown cells, which produce glyco-
proteins with well defined sugars of the type Man5NAG2 [33].
Proteins produced in this way are thought to be more suitable for
structural characterizations by protein crystallography or SAXS,
since homogenous and well defined samples are a prerequisite for
successful experiments with these two techniques. In order to
assess the importance of glycosylation, EndoEC was also overex-
pressed in HEK293 FreeStyle cells, which produce native full
glycosylation. The proteins were purified from the media by
immobilized metal ion adsorption chromatography followed by a
gel filtration polishing step, resulting in a homogeneous protein,
judged from Coomassie stained SDS gels. Typically we are able to
purify 1.5–3 mg of protein per liter of cell culture.
Analogously to endoglin, a construct for ALK1 comprising the
predicted complete ectodomain (AlK1EC residues 21–118,
Figure 1B) was cloned and purified for binding studies. ALK1EC
possesses a theoretical N-glycosylation site at Asn98. The
approximate electrophoretic mass estimate for ALK1EC produced
in HEK293S GNT1- cells was 12 kDa, and upon treatment with
EndoHf the mass was slightly reduced [34], due to enzymatic
removal of the attached glycans (data not shown), indicating that
ALK1 is indeed a glycoprotein.
In summary, our results demonstrate that the endoglin
ectodomain OD can be produced successfully in a very
homogenous soluble form when working with HEK293 FreeStyle
cells (Figures S1A, S1B and S2), as can other well defined
constructs of endoglin and ALK1 (data not shown).
Identification of a disulfide bond dimerizing endoglin
A previous report identified the juxtamembrane Cys582 as
being involved in the dimerization of endoglin via disulfide
bonding [15]. However, the involvement of additional Cys
residues in the dimerization process has been suggested [35].
Electrophoretical analysis under reducing and non-reducing
conditions of EndoEC and the OD constructs showed bands
corresponding to dimeric and monomeric species for the full
length endoglin ectodomain and for Endo362. In contrast, for
Endo338 exclusively the monomeric form was observed in both
redox states (Figure 1C). The native monomeric state of Endo338
was further confirmed by SAXS and analytical gel filtration
(Figures S1B and S2). Previously the cysteine (or cysteines)
responsible for the dimerization of endoglin was mapped to be
located in the region between Phe282 and Ser431, harboring 6
possible cysteines (Cys330, Cys350, Cys363, Cys382, Cys394 and
Cys412) that could be involved in the disulphide-mediated
oligomerization process of the ectodomains [35]. The data
presented herein therefore points to Cys350, being the only
cysteine located in the region 338–361, as a residue clearly
involved in the dimerization of endoglin (Figure S3).
Evaluation of the contribution of glycosylation to ligand
binding
BMP-9 has been described as the ligand of ALK1 [18,36] and
endoglin [28]. In order to evaluate the importance of the
glycosylation of these receptors for binding to BMP-9, we carried
out surface plasmon resonance (SPR) binding assays with EndoEC
protein produced in both HEK293S GnTI-, which incorporates
only short, well defined sugars rendering low glycosylated proteins
(LG-EndoEC), and HEK293 FreeStyle, which produce mature,
branched sugars and proteins with high glycosylation (HG-
EndoEC) (Figure 2A). Sensor chip-immobilized BMP-9 bound
LG-EndoEC and HG-EndoEC with apparent equilibrium dissoci-
ation constants (KD) of 2 nM and 10 nM respectively (Table 1,
rows 1–2), indicating that recruitment of endoglin is mainly
independent of the glycosylation state. The somewhat lower KD
value of the glycosylated endoglin form comes from both a lower
avidity (ka,0.5 times lower) and a faster dissociation (kd,2.2-fold
higher) (Table 1), suggesting that the sugar impairs to some extent
the interaction of endoglin with BMP-9. This result also
demonstrates that endoglin recognizes and binds BMP-9 in a
highly efficient and selective manner on its own, at variance with
Endoglin Ligand Recognition and Binding
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I TGF-b receptor [37,38].
Next, the contribution of glycosylation in BMP-9 binding to
ALK1 was assessed. ALK1EC produced in HEK293S GNTI- (LG-
ALK1EC) or HEK293 FreeStyle (HG-ALK1EC) cells was analyzed
by SPR using BMP-9 immobilized on the surface of the sensor
chip (Figure 2B). LG-ALK1EC and HG-ALK1EC bound to human
BMP-9 with nearly identical values for ka and kd for both forms,
resulting in KD values of 46 nM and 19 nM respectively (Table 1,
rows 3–4). Thus, the mature glycosylation of ALK1EC seems not to
affect the affinity for the substrate BMP-9.
Assessing whether the binding of endoglin and ALK1 to
BMP-9 is cooperative
Once having demonstrated that both receptors, endoglin and
ALK1, recognize and bind individually with high affinity to BMP-
9, we examined the possible cooperative nature of the interaction
and binding process, using two different approaches. The first
approach consisted in the capturing and saturation of the chip-
immobilized BMP-9 with ALK1 prior to injection of endoglin at
various concentrations (Figure 2C), while the second approach
consisted of co-injecting endoglin with constant saturating
concentrations of ALK1 onto the same chip. For both endoglin
forms, LG-EndoEC and HG-EndoEC, the KD values obtained were
mostly identical independently of the approach (Table 1, compare
row 6 with 8 and 7 with 9). Both methods yielded KD values that
were closely similar to those estimated in the absence of ALK1
(Table 1, rows 1 and 2). We also carried out the converse
experiment by saturating the BMP-9 immobilized chip with
endoglin prior to injection of ALK1 at various concentrations
(Figure 2D). Independently of the presence of endoglin, we
obtained the same kinetic constants for ALK1 binding to BMP-9
Figure 1. Schematic domain organization of human endoglin and ALK1 and western blots of endoglin domains. Bar diagram of (A)
endoglin and (B) ALK1 with the domains indicated and highlighted in different styles. TM, transmembrane region, ZP, zona pellucida. The putative
Asn glycosylation sites Asn88, Asn102, Asn121, Asn134 and Asn306 of endoglin and Asn98 of ALK1 are labelled within green ovals. The constructs
used in this study and the domains encompassed by these are shown below the bar diagram of the respective full length protein. (C) Western blots of
endoglin constructs. Endo338, Endo362 and LG-EndoEC were analyzed by 10% SDS polyacrylamide electrophoresis gel followed by western blotting
with an anti-His6 antibody. Samples reduced with dithithreitol (DTT) were incubated for 1 h with 10 mM of this reagent at 65uC. All samples (0.5 mgo f
protein) were then denaturated by boiling at 95uC for 5 minutes prior to charging onto the gel. The molecular weight markers (M) are indicated at
the left of the samples. For both Endo362 and LG-EndoEC, dimeric species are visible, while Endo338 was only observed in monomeric form.
doi:10.1371/journal.pone.0029948.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e29948Figure 2. Functional interactions between endoglin, ALK1 and BMP-9. The interactions of (A) EndoEC, (B) ALK1EC, (E) Endo338 and (F) Endo362
with BMP-9 were investigated by SPR. While HG-EndoEC and Endo362 dissociated slowly, Endo338 dissociated much faster, indicating a rigid body type
of binding as opposed to an induced fit mechanism. For affinity measurements, the indicated recombinant proteins were injected at six
concentrations ranging from 12.5 to 400 nM over BMP-9 (which was immobilized on a CM5 sensor chip by amine coupling) to generate sensorgrams
(colored curves). When testing competition between HG-EndoEC and HG-ALK1EC (C and D) the chip was first pre-equilibrated with 750 mM of either
HG-EndoEC (C, left) or HG-ALK1EC (D, left) before injecting the various concentration of the second ligand, showing the curve for the highest
concentrations of the 2
nd ligand. Both HG-ALK1EC (C, right) and HG-EndoEC (D, right) yielded, after subtracting the background, similar results to those
in runs in which no first ligand was preequilibrated before injecting the second ligand (D right vs. E; C right vs. B). This leads to the conclusion that
endoglin and ALK1 bind independently to different sites on BMP-9. The kinetic parameters for the interaction were determined by global fitting
(curves in black) of the 1:1 Langmuir binding model to these data, providing values for the association (ka) and dissociation (kd) rate constants and the
dissociation affinity constant (KD).
doi:10.1371/journal.pone.0029948.g002
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ALK1 have different binding sites on their common ligand.
Moreover, both receptors bind BMP-9 in an independent fashion,
since no cooperative effect between endoglin and ALK1 was
observed.
The endoglin orphan domain is sufficient for recognition
and binding of BMP-9
Sequence analysis of the endoglin ectodomain reveals a
characteristic ZP domain that comprises the C-terminal portion
(residues 363–561), remaining an N-terminal portion (residues 26–
362) that does not show any significant homology to other protein
consensus motifs and named, thereby, the ‘‘orphan’’ domain
(Figure 1A) [25]. Since the ZP domain is a common motif present
in a wide variety of proteins and serves to cluster and oligomerize
surface receptors, including those involving TGF-b signaling
[24,26,39], we hypothesized that the orphan domain could be the
portion of endoglin that is involved in BMP-9 binding. To test this
hypothesis, we produced two deletional endoglin constructs:
Endo362, where the predicted ZP domain has been removed
(Figure 1A), and Endo338, where a proline rich and predicted
unordered region at the OD C-terminal part (Figure S3) was
removed (Figure 1A). This small linker region (residues 338–362)
connects the orphan and ZP domains and possibly allows for
flexibility between these domains when binding to a ligand. It also
carries Cys350 that our electrophoretical analysis identified as the
possible mediator of endoglin dimerization via disulfide linkage.
Both constructs were shown to bind BMP-9, although with quite
different KD values. Endo362 presents quite similar kinetic values
to those calculated for the full endoglin ectodomain (Table 1, rows
2 and 12), with a KD value of 9 nM. However, the KD for Endo338
binding to BMP-9 was 270 nM, a value two orders of magnitude
higher than the KD for the binding of the complete ectodomain
(Table 1, rows 2 and 10). This increase in the KD is due to a faster
dissociation of the Endo338 - BMP-9 complex, while keeping the
same avidity for the ligand (Table 1, compare ka and kd values of
rows 2 and 10). These results confirm that the recognition and
binding of BMP-9 by endoglin fall on its orphan domain. We thus
have delimited the minimum interacting region to the 22–338
fragment. Comparison of EndoEC and Endo338 sensograms reveal
that the former construct associates and dissociates more slowly to
and from BMP-9 than Endo338 (Figures 2A and 2E). This suggests
rigid body rather than induced fit binding in the case of the
interactions between the orphan domain, represented by Endo338,
and BMP-9. This effect is less striking for Endo362, which behaves
like EndoEC (Figure 2F). Thus the orphan domain is needed for
recognition, while the ZP domains appear to stabilize the
extracellular portion of endoglin, enhancing the stability of the
complex, when formed [26,39].
Taking into account the fast Endo338 - BMP-9 association and
dissociation, we analyzed whether the presence of ALK1 could
have any effect on this interaction. As in the case of the full length
constructs, the presence of HG-ALK1EC did not influence the
binding nor the dissociation of Endo338 to or from BMP-9 (Table 1,
rows 10–11), indicating that the presence of the ZP domain does
not interfere with, nor contributes to BMP-9 binding.
Competitive inhibition of signaling
In order to evaluate the functionality of the proteins analyzed
we checked the effect of ALK1 and endoglin on the response
induced by BMP-9 in human microvascular endothelial cells
(HMEC-1). It is known that BMP-9 activates, through the Smad1/
5/8 pathway, the expression of ID1 [40]. Therefore we measured
by real time PCR the expression of this gene in cells treated with
75 ng/ml BMP-9 in the presence or absence of 10 mg/ml LG-
ALK1EC,1 0mg/ml LG-EndoEC and 10 mg/ml Endo338 as well as
with only the receptors for 36 hours. As expected, stimulation of
endothelial cells with 75 ng/ml BMP-9 induces a high (,7 fold)
increment of ID1 expression. This effect is specific of BMP-9, since
the supplementation with the recombinant receptors analyzed in
the assay in absence of BMP-9 has an extremely weak (1–2 fold)
effect on the expression of ID1 (Figure 3). When co-incubating
with BMP-9, both, LG-ALK1EC and LG-EndoEC diminish BMP-
9 signaling to a large extent, bringing it close to the basal value
observed when incubating the cells only with the ectodomains
(Figure 3). This is likely due to the fact that LG-ALK1EC and LG-
EndoEC are effectively sequestering BMP-9 and thus interfere with
the downstream signaling. On the other hand, the addition of
Endo338 only partially reduces the signaling. As learned from the
SPR experiments, although Endo338 recognizes and binds to
Table 1. Analysis of ligand binding to BMP-9 assessed by Surface Plamson Resonance.




1 HG-EndoEC - - 2.08E+5 2.07E23 9.94E29
2 LG-EndoEC - - 4.42E+5 8.91E24 2.01E29
3 HG-ALK1EC - - 1.21E+5 5.60E23 4.64E28
4 LG-ALK1EC - - 2.13E+5 4.03E23 1.89E28
5 HG-ALK1EC - HG-EndoEC 1.30E+5 7.72E23 5.93E28
6 HG-EndoEC HG-ALK1EC - 2.74E+5 1.53E23 1.47E28
7 LG-EndoEC HG-ALK1EC - 2.83E+5 9.25E24 3.27E29
8 HG-EndoEC - HG-ALK1EC 7.11E+5 1.09E22 1.50E28
9 LG-EndoEC - HG-ALK1EC 3.49E+5 9.13E24 2.62E29
10 Endo338 - - 9.14E+5 2.54E21 2.76E27
11 Endo338 - HG-ALK1EC 1.22E+6 1.92E21 1.55E27
12 Endo362 - - 1.20E+5 1.08E23 8.96E29
Kinetic analysis of endoglin and ALK1 binding to BMP-9 was performed in triplicates on a Biacore T100 at 25uC as described in the experimental procedures. Data were
globally fit to a 1:1 binding model using the Biacore T100 evaluation software.
doi:10.1371/journal.pone.0029948.t001
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(Table 1). This equilibrium favors the free state of BMP-9,
increasing the pool of molecules that can stimulate ID1 expression
and, consequently, decreasing only about ,50% the BMP-9
dependent signaling (Figure 3). These cell-based assays demon-
strate that the constructs used in our experiments are functional,
having the capacity to interact and to inhibit BMP-9-mediated
signaling, and they confirm the orphan domain to be the BMP-9
recognition domain of endoglin.
Low resolution structures of the orphan domain
The solution structure of Endo338 was investigated by small
angle X-ray scattering (SAXS). From the experimental scattering
curve obtained from exposing a solution of Endo338 to X-rays
(Figure 4A) the independent parameters for the radius of gyration
(Rg) and the maximal dimensions (Dmax) of the orphan domain
can be deduced. These parameters allow determining the
oligomeric state, the overall shape of the molecule and to assess
flexibility, which could arise from unordered regions. The Rg of
2.81 nm obtained from the Guinier plot (Figure S2A) and Dmax
of 9.4 nm suggest that the protein has a compact conformation
(Table 2 and Figure 4B). The relative molecular mass estimated
from I(0) and the concentration of Endo338 yielded a molecular
weight of 40 kDa through BSA calibration, confirming the
monomeric state of Endo338 in solution (Figure S2B). Further-
more, the Kratky plot, a representation related to the flexibility of
the molecule analyzed, presents a gaussian appearance (insert
Figure 4A) that indicates a well folded nature of the construct. The
overall envelope of Endo338 was calculated ab initio from its
scattering profile using bead modeling programs (see Experimental
section; the most typical shape is provided in Figure S2C),
obtaining 20 final independent DAMMIF models that were
aligned and compared with DAMAVER [41]. All models yielded
recurrent features that correspond to an average envelope of
Endo338 in solution (Figure 4C) with overall dimensions of about
95655630 A ˚ and planar ellipsoid shape, which is consistent with
a globular well folded domain. The validity of this averaged model
was supported by the reproducibility of the independent
reconstructions and the low normalized spatial discrepancy
(NSD, having a value of 0.55) between them, and their good
fitting to the experimental data (x
2=0.95). Furthermore, similar
results were obtained with DAMMIN and GASBOR [41].
With the purpose of clarifying whether the SAXS-deduced
envelope could fit the OD fold, we tried to model the structure of
this domain using existing programs for de novo model building,
since comparative modelling could not be used because of the lack
of OD homologues of known structure. We calculated de novo
models using the online I-TASSER and Robetta servers [42,43].
The best models (selected by their fit to the SAXS data evaluated
with CRYSOL [41], see Figure S4) were used as starting models
for further calculations. The outcome was an orphan domain fold
comprised of 2 separate domains. These two domains, together
with the five Man5NAG2 glycan chains (Figure 4D; modeled with
the SWEET2 online server [44]) found on the proteins surface,
were further fitted by rigid body movements using SASREF in the
experimental SAXS envelope [41]. The best final model with a fit
of x
2=1.1 is in extremely good accordance with the ab initio
SAXS-deduced shape (Figure 4D), which consists of a ,230-
residue domain corresponding to the N-terminal part of the OD,
which carries all the glycans, and which is followed by a smaller
domain of ,80 residues (Figure 4C).
Discussion
Endoglin is classified as a type III TGF-b receptor, playing a
crucial role in angiogenesis, preeclampsia and cancer. However,
the complete functional and structural analysis of the endoglin
domains remains to be elucidated. Recently, the ligands of ALK1,
namely BMP-9 and BMP-10 were identified [18,36], which
therefore were also suggested to be the native ligands of endoglin,
since both receptors were identified to be part of the same
signaling complex. Moreover, mutations in both receptors result in
HHT [4,5,6]. We therefore were interested in characterizing the
binding of endoglin to its proposed ligand BMP-9 and to the
complex ALK1 - BMP-9 in order to evaluate the putative
cooperative nature of complex formation. Towards this aim, we
expressed ALK1 and endoglin in a mammalian cell-based
expression system, which also allowed us to fine-tune the
Figure 3. Functional analysis of recombinant endoglin and ALK1 proteins. ID1 expression in BMP-9 stimulated HMEC-1 cells after 36 hours
in the presence or absence of LG-ALK1EC, Endoglin338 or LG-EndoEC. The ALK1 and endoglin ectodomains hijack BMP-9 and therefore signaling is
diminished. Endo338 only partially inhibit signaling, due to a less stable complex formed between the orphan domain and the cytokine. (*) Statistically
significant (p,0.01) difference compared to unstimulated control cells (Ctl). (#) Statistically significant (p,0.01) difference compared to ID1
expression of BMP-9 stimulated cells.
doi:10.1371/journal.pone.0029948.g003
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comprised of a ZP region and the so called ‘‘orphan domain’’ we
designed, in addition to the full length domain, truncated
constructs of the OD guided by secondary structure predictions.
Endo362 terminates at the end of the OD, just before the predicted
start of the ZP domain. Endo338, a slightly shorter construct, was
Figure 4. SAXS data analysis and rigid body modeling. (A) The experimental SAXS profile of recombinant Endo338, measured at the ID14-3
BioSAXS beamline. The Kratky plot (inserted), displays a gaussian behavior, which indicates the well folded nature of the construct. (B) The distance
distribution function, p(r) obtained from GNOM with a Dmax of 9.4 nm also suggests a compact structure. (C) The orphan domain model obtained
from I-TASSER together with 5 Man5NAG2 glycans, restricted by their attachment sites was fitted by rigid body modeling with SASREF, yielding a fit of
the model (red line) against the experimental Endo338 scattering profile (blue crosses) of x
2=1.1. The input models used, are depicted above the fit
curve. (D) The resulting model is displayed as a cartoon in three orthogonal views, with the attached sugars depicted as balls, fitted into the
molecular envelope from DAMMIF.
doi:10.1371/journal.pone.0029948.g004
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terminal end of the OD. Interestingly, the Endo362, as well as
EndoEC, dimerized to some extent through a disulfide bond, while
Endo338 was clearly a monomer. Detailed analysis mapped the
cysteine involved in endoglin aggregation at the region between
Phe282 and Ser431 which harbours 6 possible cysteines (Cys330,
Cys350, Cys363, Cys382, Cys394 and Cys412) [35]. The results
presented herein suggest that Cys350, located in the unordered
linker region spanning residues 338 to 362 between the ZP domain
and the OD, together with the reported juxtamembrane Cys582
[15], are involved in the dimerization of endoglin via disulfide
linkages. However, further studies will be needed to confirm
whether or not additional cysteines are involved in the endoglin
dimerization process. Using SPR analysis we have demonstrated
that the ectodomain of endoglin can directly bind BMP-9 in a
highly efficient manner. This observation was corroborated by the
in vivo functional assays, where the presence of either endoglin or
ALK1 effectively inhibited BMP-9-induced downstream signaling.
Furthermore, endoglin and ALK1 bind to different non-
overlapping sites on their common ligand BMP-9 as could be
demonstrated by SPR, where no change in binding kinetics was
observed when either co-injecting EndoEC with ALK1EC or pre-
equilibrating the BMP-9 bound CM5 sensor chip with ALK1EC.
However, it should be remembered that these assays were
undertaken with the receptors ectodomains. In the case of cell
signaling with the full-length membrane-embedded receptors, it is
conceivable that there may be differences with the in vitro assays in
the binding of BMP-9 to the receptor, since the intracellular and
transmembrane domains of endoglin and ALK1 might interact
with each other and promote somewhat different conformations
and modes of binding. In this regard, specific pairing interactions
among BMP-9, ALK1 and endoglin within the cell have been
suggested based on co-immunoprecipitation and cross-linking
experiments [14,19]. This in turn, also opens the possibility of
cooperativity in the binding to BMP-9 within the cellular context,
in agreement with recent in vitro data [36]. However, at variance
with a recent report [28], our experiments do not support the
existence of a synergic cooperation in the binding of these proteins
in vitro.
We also were interested in studying the contribution of the
sugars to recognition and binding of the receptors to their ligand,
BMP-9. To accomplish this aim, we have set up a protocol to
produce high amounts of well-folded and functional full-length
ectodomains of both receptors in two cell lines that yield mature
and minimal glycoforms. The disposition of high and low-
glycosylated forms of both receptors allowed us to demonstrate
that this post-transcriptional modification has little contribution to
the recognition and binding of BMP-9. In agreement with this in
vitro observation, glycosylated and PNGase F deglycosylated
endoglin ectodomain produced in CHO cells have comparable
effects in reported assays carried out in U937 cells [27]. Based on
these data, we favor the hypothesis that although glycosylation is
related to correct folding and the stability of endoglin and ALK1
at its extracellular localization [45,46], it is not involved in BMP-9
binding to the mature receptor proteins.
We have dissected endoglin in order to identify which domain is
involved in ligand binding and have found that the implicated
region lies between residues 22 and 338, which encompasses the
orphan domain. Endo338 possesses nearly identical recognition
abilities as the full length protein, judged from the ka value for this
construct. However, the Endo338 – BMP-9 complex is not very
stable as can be deduced from the high kd in its monomeric form.
The slightly longer Endo362 construct can be viewed as a dimeric
OD. This construct was bound and remained in complex with
BMP-9 in a similar fashion to the full length extracellular domain
of endoglin. Therefore the ZP domain appears not to be involved
in the binding process and may have a mere structural role at the
cellular surface.
The report by Castonguay et al. [28], published while this
manuscript was in preparation, presents important discrepancies
with our work which might be attributed to the fact that the
proteins in that study were expressed as chimeras with the
immunoglobulin Fc domain. This type of chimeras usually yield
soluble and stable proteins [47], which allowed them to carry out
an exhaustive and deep analyses, however the presence of the Fc
domain can introduce in some cases structural restrictions and
rigidity as well as mediate unspecific interactions. Specifically to
avoid similar problems, our studies were carried out with endoglin
and ALK1 proteins that do not introduce extra amino acids,
allowing us to clearly identify Endo338 as the domain that is active
in BMP-9 binding. The SPR studies by Castonguay, used to detect
endoglin interactions with its ligands and co-receptor, yielded
conclusions that are coincident with those of our study on BMP-9
recognition by the endoglin orphan domain and on the
independence of the binding sites for BMP-9 of endoglin and
ALK1. However, Castonguay and collaborators stated that their
constructs 26–329 and 26–332 showed no binding activity to
BMP-9 by SPR, and in turn identified the region 26–359 to be the
smallest of their constructs being active in binding. This activity
was attributed to either a potential a-helix in the 352–358 region
or to the need of a flexible linker between the OD and the Fc
domain to allow BMP-9 binding. Since we find that Endo338 binds
to BMP-9, the second possibility appears the most likely one for
the OD-Fc fusion chimera, raising the question on whether Fc
























Endo338 13.6 3.7 40 67.8 39 2.82/2.81/2.81 9.4 0.952 1.1
BSA 12.4 4.85 66.0 147 66.3 3.11/3.1/3.1 10.7 ND ND
aValues for I(0) have been extrapolated by the Guinier approximation from the experimental scattering profiles.
bConcentration of the protein used for the calculation of the estimated Mw.
cRelative molecular mass estimated from I(0) and the concentration of the protein through BSA calibration.
dThe Porod volume was calculated using PRIMUS [41].
eExpected molecular mass predicted from the sequence and assuming full occupation of the glycosylation sites.
fRg (Guinier), Rg (GNOM), radius of gyration given by the Guinier approximation, and calculated by the program GNOM, respectively, given in nm.
gMaximum dimension of the macromolecules. x
2 (over) Discrepancy between the SAXS profile and its fit by the overall shapes-models calculated by DAMMIF, and
x
2 (sasref) the average discrepancy of the best atomic models estimated with the program CRYSOL. ND, not determined.
doi:10.1371/journal.pone.0029948.t002
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Castonguay and collaborators found that the OD (26–378 and 26–
359 in their study) has higher affinity for BMP-9 than the full-
length ectodomain [28] in contrast to our observations that this
domain has similar (Endo362) or lower (Endo338) affinity than the
full-length ligand (Table 1, rows 12 and 10). Again, the presence of
the Fc domain, which is known to dimerize [47], could be affecting
the kinetic parameters. Indeed, the KD values calculated by these
authors are three orders of magnitude lower than in our studies
(Table 1), which might be related to the presence of the Fc
domain. The alternative possibility that this difference reflects poor
folding of the proteins used in our assays is contradicted by our
SAXS results which reveal for Endo338 a molecular envelop that
corresponds to a compact, well-folded monomer and suggested
that Endo338 does not have any overhanging flexible and
unordered ends, confirming the quality of the proteins used in
our binding assays. Indeed, the functionality of the proteins used in
the present studies was confirmed by cell-based assays in which
both endoglin and ALK1 were found to inhibit BMP-9 induced
signaling, as expected if they form stable non-functional complexes
with BMP-9, preventing this ligand from binding to its membrane-
bound receptors and the subsequent triggering of downstream
signals. This in vivo cell assay also corroborated the existence of an
interaction of the orphan domain with BMP-9, although these
assays also provided evidence that the interaction was weaker than
for the full-length ectodomain, since the signaling was not
completely abolished by the orphan domain. One remaining
question to be clarified is, if ALK1 and endoglin do bind to
different sites on BMP-9, why then is signaling reduced when only
one of the 2 proteins is added? We hypothesize that the productive
signaling complex should involve the correct spatial location of
both membrane-bound ALK1 and endoglin co-receptors. There-
fore, when BMP-9 binds to either one of the 2 soluble ectodomains
the cellular bound analogous domain cannot bind anymore to its
site, and thus the membrane complex cannot be formed, which in
turn inhibits downstream signaling. Further specific experiments,




Materials for chromatography were from Fisher Scientific.
Reagents for cell cultures were from Gibco and Lonza. Chemical
reagents and primers were purchased from Sigma-Aldrich,
EndoHf from New England Biolabs and In-Fusion enzyme from
Clontech. CM5 sensor chips, the amine coupling kit, ethanol-
amine and the P20 surfactant were from GE Healthcare. RNeasy
kit was from Qiagen. iScript cDNA Synthesis kit and iQ SyBR-
Green Supermix were from BioRad. Carrier free BMP-9 was from
R&D Systems and FreeStyle HEK293F cells from Invitrogen.
cDNA cloning
The full length endoglin ectodomain (EndoEC, residues 22–587),
its OD (Endo338, residues 22–337 and Endo362, residues 22–361)
and the ALK1 ectodomain (ALK1EC, residues 21–118) were PCR
amplified using human endoglin and ALK1 cDNAs, as templates,
and specific primers (see Sup. Table 1). Amplified fragments were
purified and inserted into the pOPING vector for expression in
mammalian cells using the In-fusion cloning system and selected
clones were verified by DNA sequencing. In this expression vector,
the constructs are fused to the m-phosphatase secretion leader
sequence and a C-terminal 6xHis tag. Cloning procedures and the
over-expression of the plasmids for transient expression were
carried out with E. coli DH5a.
Protein expression and purification
Endoglin was expressed in glycosylation-impaired HEK293S
GnT1- suspension adapted cells which produce homogeneous and
lower molecular weight sugar chains (Man5NAG2) [33]. Suspen-
sion-grown HEK293S GNT1- cells in FreeStyle medium supple-
mented with 1% foetal calf serum (FCS) were cultured at 37uC
under 5% CO2 atmosphere and shaking at 130 rpm on a
Multitron-2 incubator shaker (Infors AG, Bottmingen, CH). Upon
reaching a density of 1.5–2610
6 viable cells/ml, cells were
transfected with 1 mg DNA per liter of culture using polyethyle-
nimine (PEI) as the transfection reagent at a DNA:PEI ratio of
3.5:1. Four days after transfection, the culture supernatant
containing the secreted protein was harvested by centrifugation
at 50006g for removal of cells and debris. Subsequent steps were
at 4uC. An equal volume of PBS (pH 7.4) containing 2 mM
reduced glutathione and 20 mM oxidized glutathione was added
and the protein was loaded onto a 5-ml HisTrap column using a
peristaltic pump in a closed circuit overnight. Thereafter, the
column was washed with buffer A (100 mM Tris-HCl pH 8,
150 mM NaCl) supplemented with 20 mM imidazole and
endoglin was eluted with 350 mM imidazole. Subsequent size
exclusion chromatography was carried out in buffer A using a
HiLoad 16/60 Superdex 200 column (GE Healthcare). The pure
fractions (shown by SDS/PAGE), were pooled and concentrated
by centrifugation in an Amicon concentrator to ,20 mg/ml and
flash frozen in liquid nitrogen. Analytic size exclusion chroma-
tography was performed using a Superdex 200 10/300 GL size
exclusion column (GE Healthcare), calibrated with standards
(Sigma-Aldrich) using buffer A as the running buffer. ALK1 was
expressed and purified in an analogous manner to endoglin,
except that after the centrifugation step the culture supernatant
was not diluted in PBS before application to the HisTrap column.
Thereafter, the gel purification polishing step was performed using
a HiLoad 16/60 Superdex 75 column (GE Healthcare). Both
endoglin and ALK1 were also expressed in FreeStyle HEK293F
cells. These cells produce mature glycans and the resulting protein
was then purified in the same manner as the protein produced in
HEK293S GnT1- cells [34].
Cell culture and functional assays of recombinant
proteins
Human microvascular endothelial cells HMEC-1 were cultured
on gelatin pre-coated plates as monolayers in MCDB 131 medium
supplemented with 10% FCS 2 mM L-glutamine, 1 ng/ml EGF,
1 mg/ml hydrocortisone and 100 U/ml penicillin/streptomycin
(complete medium) in a NAPCO incubator at 37uCi na
humidified atmosphere with 5% CO2. For the functional
characterization of the recombinant proteins, inhibition experi-
ments of the BMP-9-dependent ID1 induction were carried out.
HMEC-1 cells were grown in 6-well plates to 40% confluence and
then treated with 75 ng/ml BMP-9 in the presence or absence of
10 mg/ml ALK1EC,1 0mg/ml Endo338 or 10 mg/ml LG-EndoEC,
as indicated, for 36 hours in MCDB 131 basal medium
supplemented with 2% FCS. For quantitative real time PCR
analysis, total RNA was isolated from HMEC-1 cells using the
RNeasy kit and was reverse-transcribed using iScript cDNA
Synthesis kit. Then, 1 ml of cDNA was used as a template for real
time PCR performed with specific ID1 primers (Sup. Table 1)
using the iQ SyBR-Green Supermix. Amplicons were detected
using an iQ5 real time detection system (BioRad). Transcript levels
were normalized to 18S levels (Sup. Table 1 for primers used).
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was performed on the Data Desk package (version 4.0).
Significance was estimated with analysis of variance (ANOVA)
followed by Fischers LSD test for multiple comparisons.
Surface plasmon resonance binding studies
All surface plasmon resonance experiments were carried out on
a BiacoreT100 instrument (GE Healthcare). Bone morphogenetic
protein 9 (BMP-9) was covalently immobilized via primary amino
groups on a CM5 sensor chip surface. The amount of immobilized
BMP-9 corresponded to 114, 253, 321 Response Units (RU) in
channels 1, 2, and 3 respectively. Channel 4 on the same sensor
chip, reserved for control runs, was treated in the same way as
channels 1–3, but without BMP-9 immobilization. For all SPR
measurements, the recombinant proteins were diluted in running
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA
and 0.05% detergent P20) and centrifuged immediately before the
runs to minimize possible effects from nonspecific aggregation.
The association was monitored by injecting different concentra-
tions of the analytes into all 4 channels starting with the lowest
analyte concentration. All experiments were conducted in
triplicates at 25uC at a flow rate of 30 mL/minute. Samples were
injected during 85 seconds to achieve steady-state binding and a
subsequent 600 seconds were allowed for dissociation. Between
injections surfaces were regenerated with 0.5 M NaOH at a flow
rate of 30 mL/minute for 15 seconds. For capturing experiments,
based on the Biacore T100 manual, the first analyte was injected
at a concentration of 750 nM in running buffer for 60 seconds into
all 4 channels at a flow rate of 10 mL/minute to allow for trapping
by BMP-9. Thereafter, the second analytes were injected at
different concentrations into all 4 channels starting with the lowest
analyte concentration, as described above. Another approach
consisted of coinjecting the various samples together with a
constant concentration of the competing analyte. All curves were
corrected for nonspecific binding by subtraction of control curves
obtained from injection of the corresponding protein through the
blank flow channel. Both, the affinity and dissociation constants
were calculated from the plots of the steady-state binding as a
function of protein concentration, using the Biacore T100
evaluation software (Biacore AB) and a 1:1 binding kinetic model
(Table 1).
Structural modeling of endoglin
The online servers I-TASSER [42] and Robetta [43] were used
to derive a model for the extracellular domain of endoglin,
comprising of residues 22–337. The 3D models of saccharides
were modeled with the SWEET2 online server [44]. Figures were
prepared with PyMOL [48].
Small angle X-ray scattering (SAXS) experiments
Synchrotron X-ray scattering data were collected at the ID14-3
BioSAXS beamline (ESRF, Grenoble) [49]. Endo338 was mea-
sured at several concentrations ranging from 0.6 to 3.7 mg/ml.
SAXS data were recorded at 25uC using a Pilatus 1 M detector at
a sample to detector distance of 2.43 m, covering the range of
momentum transfer 0.05,s,0.5 A ˚ 21 (s=4psin(h)/l where 2h is
the scattering angle and l=0.931 A ˚ is the X-ray wavelength). To
assess radiation damage, ten successive 10 sec exposures of protein
solutions were compared.
Data processing steps were performed using standard proce-
dures implemented in the software package PRIMUS [41]. The
forward scattering I(0) and the radii of gyration Rg were evaluated
using the Guinier approximation, assuming that at very small
angles (s,1.3/Rg) the intensity can be represented as
I(s)=I(0)exp[2(sRg)
2/3]. The maximum dimensions (Dmax) were
computed using the indirect transform package GNOM [41],
which also provides the distance distribution functions p(r)
(Figure 4B). The molecular weight (MW) of the solute was
evaluated by comparison of the forward scattering with that of a
reference solution of bovine serum albumin. The excluded volume
of the hydrated particle was computed using a standard equation
(Table 2).
Ab Initio modeling of the overall shapes. The overall
shapes of all assemblies were restored from the experimental data
by three independent programs: DAMMIF (20 runs), DAMMIN
(10 runs) and GASBOR (10 runs) [41] with no symmetry
restriction. The scattering profiles were used up to
smax=0.17 A ˚ 21 for Endo338 (Figure S1D). The low-resolution
models obtained from different runs were compared using the
program DAMAVER to give an estimate of the reproducibility of
the results inferred from the ab initio shape calculation [41]. The
damstart model, an output from the DAMAVER runs, was used in
DAMMIN as a starting model in order to obtain the final model
(Figure S2C).
Rigid body refinement of the models. De novo models
obtained from the I-TASSER and Robetta servers were compared
to the experimental SAXS data using CRYSOL [41]. Theoretical
SAXS curves were calculated from the individual models lacking
the glycans and their similarities to the experimental SAXS curves
were quantified using the x
2 value between the theoretical and
experimental curves. The best models were elected to be further
fitted by rigid body modeling. Final models were then refined
together with the 5 Man5 NAG2 glycans, restricted by their
attachment sites with SASREF (Figures 4C and D).
Supporting Information
Figure S1 SAXS analysis of Endo338 and the ab initio
bead model. (A) Guinier analysis of Endo338 SAXS data shows
linearity in the Guinier region, indicating lack of aggregation in
the sample. (B) Mass estimated from the Porod volume (67800 A ˚ 3)
indicates that Endo338 has an estimated mass of 34–45 kDa, which
is in good agreement with the calculated mass of 39 kDa for the
fully glycosylated monomeric species. (C) The damstart file,
resulting from 20 independent DAMMIF runs was used as a start
model for the subsequent DAMMIN run. The resulting ab initio
bead model is displayed in three orthogonal views. (D) The curve
(red) generated with DAMMIN up to smax=0.17 A ˚ 21 fits really
well (x
2=0.952) the experimental data (blue).
(TIF)
Figure S2 Analytic size exclusion chromatography. The
molecular weight of Endo338 in solution was estimated from the
elution profile using a calibrated Superdex 200 10/300 GL size
exclusion column (GE Healthcare) using buffer A (100 mM Tris-
HCl pH 8, 150 mM NaCl) as the running buffer. Endo338 eluted
at 15.93 ml, corresponding to ,40 kDa mass (based on column
calibration with appropriate standards). This is consistent with the
theoretical molecular weight of a monomeric and fully glycosylat-
ed species of 39 kDa (open red diamond labeled 39 shown within
the inserted calibration curve).
(TIF)
Figure S3 Secondary structure prediction for the or-
phan domain C-terminal region. Secondary structure
prediction and disorder prediction generated by the Phyre server
[50] yield a consensus for the region 352–358, highlighted in grey,
to be most likely of an unstructured nature, although PSIPRED
(http://bioinf.cs.ucl.ac.uk/psipred/) predicts a very short helix for
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Endo362 were truncated are shown in red, and Cys350 possibly
contributing to the disulfide-mediated dimerization is shown in
purple.
(TIF)
Figure S4 Validation of the Endo338 de novo models.
Models for Endo338 comprising residues 22–337 (1A–5A) were
calculated with the online servers I-TASSER [42] and Robetta
[43]. Discrepancy between the theoretical scattering curves of the
models (1B–5B, red curves) and the experimental SAXS profile
(1B–5B, blue curves) were evaluated using the program CRYSOL.
Model 3, which yielded the best x
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